||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Amryt Pharma Share Discussion Threads
Showing 951 to 974 of 975 messages
|Zak Mir says:
|What you said in your post about the BoD is libellous, JP. They could sue you, but they obviously wont even though you have made libellous comments based on no facts at all. Have a look at their business CV's. Their CV's are exemplary. You obviously don't agree; could you please post the evidence to back up your claims?|
|I bought some of these for a long term hold, hopefully an exciting ride ahead. GLA|
|Well JP if you are proved to be correct with your prediction, in 2-3 years time, I will congratulate you on your foresight. However I hope you are proved wrong and you congratulate me for my foresight. We shall see.|
Opinion: No Opinion
RE: SpreadToday 13:47MM's have killed it off!
Opinion: No Opinion
SpreadToday 13:3012% amazing..
Rubbish. The quoted spread is 17.50 - 19.50p, but the actual spread is 17.50 - 18.60p since one can sell at 17.50p and buy at 18.60p.|
|Interview about 11 minutes in. Talk of potential Euro 1.3b market.
|Will the recent newsflow be enough to propel the share price back to the 24p placing price, or will we have to await more good news before that happens? If only I could predict the future! LOL.
Prepared to be patient and continue to hold for the phase III trial results. I'm gambling holding AMYT will make me an excellent profit within 2-3 years. I'm excited by AMYT's prospects and the BoD. Fingers crossed!|
|Friel leaves, share price goes up.
Come on JP..a golden opportunity...
|It won't stop him whingeing.|
|JP is always omplaining about the BoD and what they earn for doing SFA (his opinion only!!). Well one of them has now departed! Good news, JP?|
|Or really that soon, so by the end of March..interesting. May take a stake|
|Getting plugged by shareprophets again.|
|When is Phase III news likely?|
|Nice stream of buys this am...|
Probably a good sign in terms of AMRYT's future|
|Cathal moving on|
|I thought the share price would drift down today, but the Beaufort speculative buy recommendation (plus the Stifel Nicolaus buy reaffirmation) has encouraged buyers and the share price is up today on good volume. Whether this uptrend will continue and lead to a re-rating, or whether it will soon fizzle out, who can know? Whatever happens I will continue to be patient and continue to hold for (hopefully!!) successful phase III news. Fingers crossed!!|
|Stifel Nicolaus reaffirmed their buy rating on shares of Amryt Pharma PLC (LON:AMYT) in a research report released on Monday morning. Stifel Nicolaus currently has a GBX 49p target price on the stock.|
|Amryt Pharma (LON:AMYT, 17.11p) – Speculative Buy
Amryt Pharma, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, yesterday announces that it has been granted a patent in Japan for its lead drug candidate, AP101 (Episalvan), for the treatment of Epidermolysis Bullosa (‘EB’). This follows similar patent grants secured in the US (September 2016) and in Europe (March 2016) as well as other patent grants in other territories, including Canada and Australia. EB is a rare and distressing genetic skin disorder which causes exceptionally fragile skin, affecting approximately 500,000 people worldwide, for which there is currently no treatment available. Amryt Pharma’s CEO, Joe Wiley, commented “We are delighted to announce that AP101 (Episalvan) has been granted a patent in Japan for the treatment of EB, widening the scope of our potential marketplace.”
Our view: Expanding its geographical reach for EB into Japan is a positive move for Amryt. In the US and EU where the Group already been granted patents with orphan drug designation, there are approximately 30,000 and 35,000 patients respectively. In Japan, the Minister of Health, Labour and Welfare has also granted orphan drug status and, according to DebRA Japan, a nonprofit support association for EB patients, there exists approximately 2,000-3,000 patients in Japan. Globally there amounts to some 500,000 people living with EB for which the market opportunity is estimated to be worth around €1.3bn per annum. Amryt expects to enter a pivotal Phase 3 clinical trial of AP101 (Episalvan) for EB in late Q1 2017. The Group has already received marketing approval for its AP101’s treatment of partial-thickness wounds from the European Commission in January 2016, having successfully demonstrated accelerated healing compared to standard therapy. Recently, the Group has also announced positive pre-clinical study results for its drug compound, AP102, for treating patients with resistant acromegaly. Acromegaly is a rare and very distressing disorder which leads to excess growth of the body’s tissues over time and it also has orphan drug designation from the US FDA. Amryt is now progressing AP102 towards clinical trials commencing this year. Amryt has an attractive mix of approved, late stage and early stage products focused on rare and orphan conditions where there is significant unmet need. They have made excellent progress in the short time since its Admission through Reverse Takeover of Fastnet Equity plc on 18 April and expect this to continue going forward. Despite making excellent progress over the past 9 months, the shares still to trade below the placing price of 24p and now offer scope for a significant re-rating. Beaufort continues to recommend the shares as a Speculative Buy.|
|Amryt Pharma's COO says Japan patent further boosts potential of lead candidate
|Holding and/or buying AMYT shares is a gamble, but a good gamble IMO. One I'm prepared to take. I'm prepared to wait for the good news that will propel the shares upwards. Fingers crossed!!|
|Being able to buy below the notional mid price is often a sign that the share price has further to fall, speecy.
Yes, Buffy, what you say is true. Unfortunately the news that AMYT is currently issuing (RNS's yesterday and today) is not ground breaking enough to propel the share price upwards unlike the two RNS's issued in December.|
|Interesting that all the transactions are showing as sells today. My 5,734 at 17.27p was a buy, so I suspect most of the trades 7.2p-7.3p could be buys and the spread could be much narrower than it looks.|
|No, there isn't currently. That's often how it is with biopharmas; but it can change dramatically. Hence the attraction.